| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.4 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |